Polylactic Acid Toxicity
Identifiers
Functions
Hazards
What are the material safety considerations for polylactic acid?
Polylactic acid is considered safe under current practices of use and concentration, based on a rat toxicity summary. No GHS hazard classifications or exposure limits are available in the supplied evidence, so no standardized hazard statements or occupational exposure thresholds can be cited. In cosmetic applications, it is listed as an active abrasive ingredient without restrictions or maximum concentration limits. The absence of GHS data does not confirm absence of hazard; it indicates a gap in standardized classification. For formulation decisions, rely on the positive safety summary but recognize that quantitative hazard data are missing.
How should hazard classifications and toxicology findings for polylactic acid be interpreted together?
The available toxicology evidence is predominantly clinical and device-oriented, focusing on injectable poly-L-lactic acid for cosmetic use. A rat toxicity summary states the ingredient is safe in present practices, but this is not a formal risk assessment. Human exposure studies describe biocompatibility and biodegradability with effects lasting up to 25 months, but they do not provide dose-response or systemic toxicity data. The absence of GHS classifications means the evidence cannot be extrapolated to occupational or environmental hazard profiles. Interpret the safety conclusion as specific to the evaluated use contexts, not as a blanket approval for all applications.
Which exposure routes, dose contexts, or effects are material for polylactic acid?
Material exposure routes include subcutaneous injection for cosmetic use and oral administration in animal studies. For injectable use, key effects are local: avoid use in areas with active skin inflammation or infection, avoid superficial injections, and take care in thin-skin areas. Periorbital safety and effectiveness are not established. No systemic toxicity, reproductive, or chronic exposure data are provided. The oral route appears in a non-human acute exposure study, but no quantitative results are given. For product development, the primary risk is local injection-site reaction, not systemic toxicity, based on the supplied evidence.
Which handling and risk-management measures are relevant for polylactic acid?
Handling controls focus on moisture sensitivity and storage integrity: keep containers tightly closed in a dry, well-ventilated place, store under inert gas, and avoid freezing. For injectable poly-L-lactic acid, use single-use vials, do not resterilize, and discard any reconstituted product after 72 hours. Clinical risk management includes deferring use in active skin inflammation or infection, injecting only into deep dermis or subcutaneous layers, and avoiding overcorrection. These measures are procedural rather than exposure-limit-based, reflecting the absence of occupational exposure thresholds. For cosmetic abrasive use, no specific handling restrictions are provided.
Which safety evidence gaps should be resolved before making decisions about polylactic acid?
The most critical evidence gap is the complete absence of GHS hazard classifications and exposure limits, which prevents standardized risk communication and occupational safety benchmarking. Additionally, no toxicological data are provided for the abrasive cosmetic use, despite its active regulatory status. The available safety summary is qualitative and does not include dose-response, repeat-dose, or reproductive toxicity data. For injectable use, long-term efficacy is documented, but systemic safety beyond local effects is not characterized. Resolving these gaps—particularly obtaining GHS classifications and route-specific toxicology—is essential before expanding applications beyond current cosmetic and device uses.